Uncategorized
Luminate meets primary endpoint in phase 2b trial for DME
Allegro Ophthalmics’ phase n2b stage 2 DEL MAR study of Luminate for diabetic macular edema has met its primary endpoint, according to a company press release.The double-masked, placebo-controlled, randomized, multicenter clinical trial had five arms and evaluated Luminate, a first-in-class integrin peptide therapy, as a sequential therapy or in combination with anti-VEGF in 80 patients, the release said.